Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists engineer self-destructing bacteria to kill cancer cells
Salmonella bacteria
Hasty and his team synchronised the bacteria to release bursts of known cancer drugs when a bacterial colony self-destructs within the tumour.
In vivo method minimises damage to surrounding cells

Scientists at the University of California and the Massachusetts Institute have discovered a therapeutic approach to cancer that minimises damage to surrounding cells.

A study published in the journal Nature describes how researchers engineered self-destructing bacteria that release anti-cancer drugs within tumours.

“In synthetic biology, one goal of therapeutics is to target disease sites and minimise damage,” said lead author Jeff Hasty, professor of bioengineering and biology at UC San Diego.

In the study, Hasty and his team synchronised the bacteria to release bursts of known cancer drugs when a bacterial colony self-destructs within the tumour.

Researchers say the use of bacteria to deliver cancer drugs in vivo is 'enticing' because conventional chemotherapy doesn't always reach the inner regions of a tumour.

Importantly, the researchers observed the combination of chemotherapy and the gene products produced by the bacterial circuit consistently reduced tumour size.

“The new work by Jeff Hasty and team is a brilliant demonstration of how theory in synthetic biology can lead to clinically meaningful advances,” said Jim Collins, a founder of the field of synthetic biology.

“Over a decade ago during the early days of the field, Jeff developed a theoretical framework for synchronising cellular processes across a community of cells. Now his team has shown experimentally how one can harness such effects to create a novel, clinically viable therapeutic approach.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.